AKT1 and non-small cell lung carcinoma: Taken together, our findings suggest DARPP-32 promotes dimerization of active EGFR and ERBB3 receptors to stimulate PI3K/AKT/mTOR and MEK/ERK signaling in EGFR TKI-refractory NSCLC progression.